Cardiovascular Drugs: Global Markets & Developments

	1 Executive Summary	

	1.1 Scope and Objectives of Report	

	1.2 Methodology	

	1.3 Competitive Overview	

	2 Cardiovascular Drug Classes	

	2.1 Adrenergic Blockers	

	2.2 Adrenergic Stimulators	

	2.3 Angiotensin Converting Enzyme Inhibitors	

	2.4 Angiotensin II Receptor Antagonists	

	2.5 Anticoagulants	

	2.6 Antidysrhythmics	

	2.7 Antihyperlipidemics (Statins)	

	2.8 Antiplatelet Agents	

	2.9 Calcium Channel Blockers	

	2.10 Diuretics	

	2.11 Glycosides	

	2.12 Thrombolytics	

	2.13 Vasodilators	

	2.14 Other Cardiovascular Drugs: Inversine, Natrecor	

	3 Emerging Drugs and New Indication Approvals	

	3.1 ACE Inhibitors and Angiotensin Receptor Antagonists	

	3.1.1 Atacand (candesartan/hydrochlorothiazide, AstraZeneca)	

	3.1.2 Benicar (olmesartan medoxomil/ hydrochlorothiazide,	

	Sankyo Pharma/Forest Laboratories)	

	3.1.3 Diovan (valsartan, Novartis)	

	3.1.4 Cozaar (losartan potassium, Merck)	

	3.2 Anticoagulants	

	3.2.1 Exanta (ximelagatran, AstraZeneca)	

	3.3 Beta-Blockers	

	3.3.1 Coreg (carvedilol, GlaxoSmithKline)	

	3.3.2 InnoPran (propranolol HCl, Reliant Pharmaceuticals)	

	3.4 Calcium Channel Blockers	

	3.4.1 Cardizem (diltiazem, Biovail/Reliant Pharmaceuticals)	

	3.4.2 Lercanidipine (Forest Laboratories)	

	3.4.3 Norvasc (amlodipine, Pfizer)	

	3.5 Antihyperlipidemics (Statins)	

	3.5.1 Crestor (rosuvastatin, AstraZeneca)	

	3.5.2 Lescol (fluvastatin, Novartis/Reliant Pharmaceuticals)	

	3.5.3 Altocor (lovastatin, Andrx)	

	3.5.4 Lipitor (atorvastatin, Pfizer)	

	3.6 Thrombolytics	

	3.7 Other Cardiovascular Drugs	

	3.7.1 Inspra (eplerenone, Pfizer/Pharmacia)	

	3.7.2 BiDil (NitroMed)	

	3.7.3 Vanlev (omapatrilat, Bristol-Myers Squibb)	

	3.7.4 Ventavis (iloprost, Schering/CoTherix)	

	3.7.5 Zetia (ezetimibe, Merck/Schering-Plough)	

	3.7.6 Ezetrol (ezetimibe, Merck Frosst/Schering Pharmaceuticals)	

	3.7.7 Pravigard Pac (pravastatin, Bristol-Myers Squibb)	

	3.7.8 Advicor (niacin/lovastatin) and Niaspan (niacin) (Kos Pharmaceuticals)	

	3.7.9 Remodulin (treprostinil sodium, United Therapeutics)	

	4 World Market Analyses and Forecasts	

	4.1 Total World Market Size and Growth for Cardiovascular Drugs	

	4.2 Adrenergic Blockers Market	

	4.3 Adrenergic Stimulators Market	

	4.4 ACE Inhibitors Market	

	4.5 Angiotensin II Receptor Antagonists Market	

	4.6 Anticoagulants Market	

	4.7Antidysrhythmics Market	

	4.8 Antihyperlipidemics (Statins) Market	

	4.9 Antiplatelet Agents Market	

	4.10 Calcium Channel Blockers Market	

	4.11 Diuretics Market	

	4.12 Glycosides Market	

	4.13 Thrombolytics Market	

	4.14 Vasodilators Market	

	4.15 Other Cardiovascular Drugs	

	5 Competitive Analysis	

	6 Research and Development	

	7 Market Trends	

	7.1 Current Cardiovascular Studies	

	7.1.1 HOPE-TOO	

	7.1.2 CORONA, JUPITER, AURORA	

	7.1.3 CRUSADE	

	7.1.4 Beta-Adrenergic and Angiotensin II Receptors	

	7.1.5 LOX-1 Gene	

	7.1.6 Gene Therapy	

	7.1.7 Gene Modification	

	7.1.8 Women’s Health Initiative and Estrogen	

	7.2 Education	

	7.3 Angiogenesis	

	7.4 Role of Angiotensin II Receptor Blockers	

	8 Company Briefs	

	8.1 Abbott Laboratories	

	8.2 AstraZeneca plc	

	8.3 Aventis Pharma AG	

	8.4 Banyu Pharmaceutical Co., Ltd.	

	8.5 Bayer AG	

	8.6 Biovail Corp.	

	8.7 Boehringer Ingelheim	

	8.8 Bristol-Myers Squibb Co.	

	8.9 Daiichi Pharmaceutical Co., Ltd.	

	8.10 Eli Lilly & Co.	

	8.11 Genentech, Inc.	

	8.12 GlaxoSmithKline plc	

	8.13 Merck & Co., Inc.	

	8.14 Millennium Pharmaceuticals, Inc.	

	8.15 Novartis AG	

	8.16 Pfizer, Inc.	

	8.17 Roche Laboratories	

	8.18 Sankyo Co., Ltd.	

	8.19 Sanofi-Synthelabo	

	9 Company Directory